ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 0613

A Baseline Kidney Biopsy Is Not Always Feasible in Incident Lupus Nephritis: Insights From an Inception Cohort
Abstract Number: 0614

Evaluating Cardiovascular Risk in Systemic Lupus Erythematosus: Comparing Novel Risk Scores with Carotid Ultrasound
Abstract Number: 0615

Systemic Lupus Erythematosus Flares in Patients with End-Stage Kidney Disease on Renal Replacement Therapy or after Transplant
Abstract Number: 0616

Neurofilament Light Chain Serum Levels is Associated with Neuropsychiatric Manifestations and Cognitive Dysfunction in Systemic Lupus Erythematosus Patients: A Longitudinal Study
Abstract Number: 0617

Autoantibodies to Extracellular Antigens in Lupus Patients Serum Versus Controls; Predominance of Autoantibodies to Type I Interferons in Lupus Sera
Abstract Number: 0618

Therapeutic landscape of systemic lupus erythematosus pure membranous nephropathy: a nationwide population-based study
Abstract Number: 0619

Interim Analysis of the Impact of a Recombinant Herpes Zoster Vaccine on Systemic Lupus Erythematosus: A Randomized Controlled Study on Immunogenicity, Safety and Immunosuppressor Effects
Abstract Number: 0620

The usefulness of neutrophil-to-lymphocyte ratio as a biomarker to predict lupus flares in patients under remission
Abstract Number: 0621

Risk Factors for Pulmonary Manifestations in GLADEL 2.0, a Systemic Lupus Erythematosus Latin American Cohort
Abstract Number: 0622

Shrinking Lung Syndrome in Systemic Lupus Erythematosus: A Pooled Database Analysis of Clinical, Immunological and Therapeutic Factors Impacting Outcomes
Abstract Number: 0623

Cluster Analysis of Socioeconomic and Environmental Determinants Modifying Activity, Chronicity and Clinical Manifestations of Systemic Lupus Erythematosus in the GLADEL 2.0 Cohort
Abstract Number: 0624

Polygenic risk of lupus is differentially associated with individual EHR-derived classification criteria
Abstract Number: 0625

DNA methylation patterns in systemic lupus erythematosus associated with nephritis status
Abstract Number: 0626

Evaluation of Novel Anti-ATP1A1 Autoantibodies by ELISA to Predict Cardiac Neonatal Lupus (Cardiac-NL)
Abstract Number: 0627

Marked Decline in SLE Mortality Despite Rising Mortality in the General Population During the COVID-19 Pandemic

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].